Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 2/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774856 | 1.00 | LTA4H (0.41) | LTA4HALDH1A1KMT2ACTSKMMP1 | |
| SCHEMBL13500185 | 0.98 | LTA4H (0.39) | LTA4HALDH1A1KMT2ACTSKMMP1 | |
| SCHEMBL13500184 | 0.95 | MMP1 (0.36) | LTA4HALDH1A1KMT2ACTSKMMP1 | |
| SCHEMBL13500187 | 0.92 | MMP1 (0.33) | LTA4HALDH1A1KMT2ACTSKMMP1 | |
| SCHEMBL13499646 | 0.84 | LTA4H (0.47) | LTA4HALDH1A1KMT2ACTSKMMP1 | |
| SCHEMBL13463206 | 0.83 | EPHX1 (0.38) | LTA4HALDH1A1KMT2ACTSKNPSR1 | |
| SCHEMBL13501734 | 0.83 | LTA4H (0.40) | LTA4HALDH1A1KMT2ACTSKMMP1 | |
| SCHEMBL13435000 | 0.82 | CPB2 (0.40) | LTA4HALDH1A1KMT2ACTSKNPSR1 | |
| SCHEMBL19817274 | 0.82 | GRIK1 (0.46) | LTA4H | |
| SCHEMBL432458 | 0.82 | GRIK1 (0.46) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| EP-2167609-A1 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009096996-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | LTA4H 929/4885ALDH1A1 1056/4885KMT2A 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.